Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply

Val Gebski¹, James Chih-Hsin Yang^{2

3}, Chee Khoon Lee^{1

4}

Affiliations

¹ National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
² Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan.
³ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
⁴ Cancer Care Centre, St George Hospital, Sydney, New South Wales, Australia.

Comment

Val Gebski et al. JAMA Oncol. 2018.

. 2018 Aug 1;4(8):1138-1139.

doi: 10.1001/jamaoncol.2018.1105.

Val Gebski¹, James Chih-Hsin Yang^{2

3}, Chee Khoon Lee^{1

4}

¹ National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
² Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan.
³ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
⁴ Cancer Care Centre, St George Hospital, Sydney, New South Wales, Australia.

No abstract available

Comment on

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Lee CK, et al. JAMA Oncol. 2018 Feb 1;4(2):210-216. doi: 10.1001/jamaoncol.2017.4427. JAMA Oncol. 2018. PMID: 29270615 Free PMC article.
Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis.
Uno H, Tian L, Wei LJ. Uno H, et al. JAMA Oncol. 2018 Aug 1;4(8):1137-1138. doi: 10.1001/jamaoncol.2018.1087. JAMA Oncol. 2018. PMID: 29931103 Free PMC article. No abstract available.